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   For 200 dogs, the degrees of palatability of two beef-based chewable formulations were compared: ‘Cardomec 
Chewable P’ aggregate (Boehringer Ingelheim Animal Health Japan Co., Ltd., Tokyo, Japan) and ‘Ivermec PI’ 
aggregate (Fujita Pharmaceutical Co., Ltd., Tokyo, Japan). They respectively contained ivermectin and pyrantel 
embonate (pyrantel pamoate) as active ingredients. Of the 200 dogs, 192 (96%) voluntarily consumed ‘Cardomec 
Chewable P’ within 1–25 (median 6) s; 197 (98.5%) voluntarily consumed ‘Ivermec PI’ within 1–21 (median 4) s. 
When the two drugs were presented simultaneously to the 200 dogs, 78 dogs consumed ‘Cardomec Chewable P’ and 
119 dogs consumed ‘Ivermec PI’. Three dogs consumed neither drug. Results show that the ‘Ivermec PI’ palatability 
is higher than that of ‘Cardomec Chewable P’ in dogs. This difference in palatability is inferred as deriving from 
different varieties and qualities of beef used as a pharmaceutical excipient when compounding and formulating the 
chewable products. 
 





   Chewable formulations containing ivermectin and 
pyrantel embonate (pyrantel pamoate) as active 
ingredients have been used extensively worldwide for 
prophylaxis of canine heartworm disease and for 
elimination of roundworms and hookworms in dogs 
[4, 5, 15, 16, 18, 19]. Generic drugs incorporating 
these ingredients have been developed in many 
countries, including Japan [7]. Most of these generic 
drugs, similarly to the branded drug, were developed 
for administration as chewable formulations [7], 
intended primarily for voluntary consumption by 
dogs. The generic drugs are thought to be equivalent 
to the branded drug in their efficacy [8, 17]. However, 
their respective degrees of palatability differ among 
the different chewable formulations because the 
varieties and qualities of meats such as beef, which 
are compounded to constitute chewable formulations, 
differ among the drugs. 
   We previously examined the respective degrees of 
palatability of the branded drug of this formulation 
and one generic drug of Japanese manufacturer. 
Results demonstrated that 97% and 99% of the dogs 
voluntarily consumed each drug, respectively [10, 14]. 
For those studies, however, each study examined 
different dogs for the branded and the generic product. 
In fact, the degrees of palatability of the two drugs 
were not compared directly. This study was 
conducted to compare the degrees of palatability of 
the two drugs using each drug with the same dog. 
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2. Materials and Methods 
2-1 Drugs 
   The branded drug and the generic drug of 
Japanese manufacturer, which respectively contained 
ivermectin and pyrantel embonate as active 
ingredients, were evaluated. The original drug 
aggregate is configured with ‘Cardomec Chewable P 
34’, ‘Cardomec Chewable P 68’, ‘Cardomec 
Chewable P 136’, and ‘Cardomec Chewable P 272’ 
(Boehringer Ingelheim Animal Health Japan Co., Ltd., 
Tokyo, Japan). The generic drug aggregate is 
configured with ‘Ivermec PI-34’, ‘Ivermec PI-68’, 
‘Ivermec PI-136’, and ‘Ivermec PI-272’ (Fujita 
Pharmaceutical Co., Ltd., Tokyo, Japan). 
   Contents of ivermectin and pyrantel embonate 
were 34 µg and 81 mg, respectively, in ‘Cardomec 
Chewable P 34’ (about 2.47 g) and ‘Ivermec PI-34’ 
(about 2.3 g), 68 µg and 163 mg, respectively, in 
‘Cardomec Chewable P 68’ (about 4.95 g) and 
‘Ivermec PI-68’ (about 4.6 g), 136 µg and 326 mg, 
respectively, in ‘Cardomec Chewable P 136’ (about 
6.43 g) and ‘Ivermec PI-136’ (about 5.5 g), and 272 
µg and 652 mg, respectively, in ‘Cardomec Chewable 
P 272’ (about 7.53 g) and ‘Ivermec PI-272’ (about 6.0 
g). Both of the two drug aggregates contain beef in 
their pharmaceutical excipients to formulate the 
chewable formulations, with the expectation of 
achieving high palatability in dogs. 
 
2-2 Animals 
   This study, conducted in Japan, examined 200 
dogs of various breeds, 105 females of which 57 had 
been ovariohysterectomized or ovariectomized and 
95 males of which 47 had been orchiectomized, 3 
months to 14 years old, with 2.9–38.5 kg of body 
weight. 
   The dogs were those of juveniles which had not 
experienced an infection season of Dirofilaria immitis, 
those which were considered not to have been 
parasitized by D. immitis based on the infallible 
medicine history of prophylactic drugs, or those 
confirmed to be negative in both microfilariae and 
adult antigen of D. immitis. At that time, detection of 
microfilariae was done by acetone testing of 
concentration method examining anticoagulated 
whole blood with ethylenediaminetetraacetic acid 
dipotassium salt (EDTA-2K) after collection from the 
cephalic vein of the left or right forelimb. The adult 
antigen was tested using a test kit (SNAP Heartworm 
RT Test; IDEXX Laboratories, Inc., Tokyo, Japan), 
using the serum separated by conventional means 
after blood collection from the same vein as described 
above. 
   Administration of the evaluated drugs was 
planned as a usual and routine prophylactic procedure 
against dirofilariasis in each dog at each guardian’s 
home based on agreement of each guardian. Rearing 
conditions such as locations and foods were not 
changed for this study. They were the same as those 
used before. No veterinary treatment was given to 
dogs during the study, except for administration of 
the evaluated drugs. 
 
2-3 Procedures for evaluating voluntary consumption 
of drugs by dogs 
   The dogs were grouped to 100 replicates, 
consisting of two animals each, in the order of 
induction to the study. The two dogs of each replicate 
were then assigned randomly to the two test groups 
using a random number table of our own making with 
C language. Dogs of one group (test group A) were 
first administered ‘Cardomec Chewable P’ and 
secondly ‘Ivermec PI’. Dogs of the other group (test 
group B) were first administered ‘Ivermec PI’ and 
secondly ‘Cardomec Chewable P’. The two 
administrations of medications were done with 
one-month intervals. 
   The administration of the drugs was done for the 
respective dogs at three hours after feeding of their 
routine diets. The drug was presented under the nose 
of each dog. The time (seconds) until the dog 
voluntarily took the drug was measured. For cases in 
which the dog did not consume the drug within 30 s, 
the drug was judged as ‘not consumed’. Furthermore, 
when the whole of the drug was not swallowed or a 
part of the drug was expelled by the dog, the drug 
was also judged as ‘not consumed’, even if the dog 
voluntarily ingested the drug once. 
   Dosages of ‘Cardomec Chewable P’ and ‘Ivermec 
PI’ were based on the recommendation of the drugs: 
prescribed administration reference quantities of 6 
µg/kg body weight for ivermectin and 14.4 mg/kg for 
pyrantel embonate. Therefore, ‘Cardomec Chewable 
P 34’ or ‘Ivermec PI-34’ was presented to dogs with 
body weight of 5.6 kg or less, ‘Cardomec Chewable P 
68’ or ‘Ivermec PI-68’ was presented to dogs with 
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body weight of 5.7–11.3 kg, ‘Cardomec Chewable P 
136’ or ‘Ivermec PI-136’ was presented to dogs with 
body weight of 11.4–22.6 kg, and ‘Cardomec 
Chewable P 272’ or ‘Ivermec PI-272’ was presented 
to dogs with body weight of 22.7–45.3 kg. 
 
2-4 Procedures for evaluating selectivity of drugs by 
dogs 
   At one month after the study described above for 
evaluating voluntary consumption, the 200 dogs’ 
selection of drugs was assessed. The two drugs, 
‘Cardomec Chewable P’ and ‘Ivermec PI’, were 
presented simultaneously under the nose of each dog. 
Which drug was consumed voluntarily by the dog 
was observed. 
   For this examination, the two drugs were put on a 
plastic-made tray of 50 cm × 30 cm at a distance of 
30 cm between the two drugs. Presentation of the 
drugs was adapted for equalization of interest of dogs 
against the two drugs: the midline of the distance 
separating the two drugs was brought under the dog’s 
nose. 
   After consumption of one drug by the dog, the 
tray was removed immediately from the front of the 
dog to avoid consumption of both presented drugs. 
When neither of the two was consumed by a dog 
during 30 s, a judgment was made that ‘the drugs 
were not consumed’. 
 
2-5 Observation of adverse events 
   General findings of the dogs were observed 
carefully and circumstantially by each guardian 
during the day of drug administration and the next 
day to note any adverse event. 
 
2-6 Ethics 
   Medications used for this study were done as a 
usual and routine prophylactic procedure against 
dirofilariasis and are therefore a necessary clinical 
treatment. In addition, the dogs were all treated with 
due consideration of animal welfare during the 
research based on the “Regulations for Animal 
Experimentation at the General Incorporated 
Association, Katsuragi Institute of Life Sciences” 
(authors’ former affiliation) under approval by the 
Institutional Animal Care and Use Committee. 
 
3. Results 
3-1 Voluntary consumption of drugs by dogs 
   For test group A, in which dogs were first tested 
with ‘Cardomec Chewable P’ and secondly with 
‘Ivermec PI’, 95 and 98 of the 100 dogs voluntarily
 
Table 1  Voluntary consumption of the branded drug ‘Cardomec Chewable P’ by dogs 
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 Fig. 1  Frequency distribution of the times until voluntary consumption of the branded drug ‘Cardomec  
 Chewable P’ by dogs 
  ‘Cardoemc Chewable P 34’,    ‘Cardoemc Chewable P 68’, 
  ‘Cardoemc Chewable P 136’,   ‘Cardoemc Chewable P 272’ 
 The figure is drawn after excluding eight dogs that did not consume voluntarily the drug. 
 
consumed ‘Cardomec Chewable P’ and ‘Ivermec PI’, 
respectively. All the dogs were confirmed to have 
swallowed the entire drug completely when they had 
once taken the drug in the mouth. The times until the
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 Fig. 2  Frequency distribution of the times until voluntary consumption of the generic drug ‘Ivermec PI’  
 by dogs 
  ‘Ivermec PI-34’,    ‘Ivermec PI-68’, 
  ‘Ivermec PI-136’,   ‘Ivermec PI-272’ 
 The figure is drawn after excluding three dogs that did not consume voluntarily the drug. 
 
dogs voluntarily took the drug were 2–25 (6 in 
median) s for ‘Cardomec Chewable P’ and 1– 17 (4 
in median) s for ‘Ivermec PI’ (Tables 1 and 2). 
   For test group B, in which dogs were first tested 
with ‘Ivermec PI’ and secondly with ‘Cardomec 
Chewable P’, 99 and 99 of the 100 dogs voluntarily 
consumed ‘Ivermec PI’ and ‘Cardomec Chewable P’, 
respectively. Furthermore, in this test group, as with 
test group A, all the dogs were confirmed to have 
swallowed the entire drug completely when they had 
once taken the drugs in the mouth. The times until the 
dogs voluntarily consumed the drug were 1–21 (4 in 
median) s for ‘Ivermec PI’ and 1–24 (6 in median) s 
for ‘Cardomec Chewable P’ (Tables 1 and 2). 
   Comparison of the results in test groups A and B 
revealed no differences in the number of dogs 
consuming each drug and the times until voluntary 
consumption of the drugs. Based on this information, 
results in the two test groups were added together as 
follows. The numbers of dogs which voluntarily 
consumed the drugs were 192 (96%) for ‘Cardomec 
Chewable P’ and 197 (98.5%) for ‘Ivermec PI’. No 
significant difference was found between the 
numbers of these dogs by chi-square testing with a 
 
 
Fig. 3  Correlation between times until voluntary 
consumption of the branded drug ‘Cardomec Chewable P’ 
and the generic drug ‘Ivermec PI’ by dogs 
The figure is drawn after excluding eight dogs that did not 
voluntarily consume either drug. Duplicate dots are omitted 
from the figure.
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Table 3  Summary of dogs that did not voluntarily consume the branded drug ‘Cardomec Chewable P’ and/or the generic 
drug ‘Ivermec PI’ 
 
 
significance level set at 5%. The times until voluntary 
consumption were 1–25 (6 in median) s for 
‘Cardomec Chewable P’ and 1–21 (4 in median) s for 
‘Ivermec PI’ (Tables 1 and 2). The frequency 
distribution of the times until voluntary consumption 
for each drug, as shown in Figs. 1 and 2, revealed that 
many dogs consumed ‘Cardomec Chewable P’ within 
4–8 s (first quartile–third quartile, see Table 1) and 
consumed ‘Ivermec PI’ within 2–6 s (first 
quartile–third quartile, see Table 2). The times for 
‘Ivermec PI’ were found to be significantly shorter 
than those for ‘Cardomec Chewable P’ by Wilcoxon 
rank sum test at a significance level of 5%. 
   High correlation was confirmed between the 
times until voluntary consumption for ‘Cardomec 
Chewable P’ and ‘Ivermec PI’, with a correlation 
coefficient (r) of 0.850. However, many dogs 
consumed ‘Ivermec PI’ within a shorter time than 
‘Cardomec Chewable P’, as reflected by the 
regression coefficient or the regression line slope (Fig. 
3). 
   Eight dogs did not consume ‘Cardomec Chewable 
P’ voluntarily. Three of the eight dogs did not also 
consume ‘Ivermec PI’. Many dogs which did not 
consume the drugs were small-breed dogs. Interviews 
with the guardians of these dogs demonstrated that 
six of the eight dogs showed an unbalanced diet in 
ordinary feeding and did not accept foods of many 
varieties, although they did not dislike meats (Table 
3). 
 
3-2 Selectivity of drugs by dogs 
   When presenting the two tested drugs 
simultaneously to the 200 dogs, 78 and 119 dogs 
respectively chose ‘Cardomec Chewable P’ and 
‘Ivermec PI’. Three dogs consumed neither drug. The 
number of dogs which chose ‘Ivermec PI’ was found 
to be significantly larger than the number which 
chose ‘Cardomec Chewable P’ by chi-square testing 
at a significance level of 5% (Table 4). 
 
3-3 Adverse events 
   No dogs showed changes in activity, appetite, or 
other general findings. They did not develop 
symptoms such as tremor, sialorrhea, vomition, and 
diarrhea after taking the drugs. The dogs developed 
no abnormality such as roughing of the hair coat, 
alopecia, or skin redness. 
 
4. Discussion 
   Ivermectin, a macrocyclic compound, shows high 
killing effects for various parasite species of 
nematodes and arthropods [3]. Pyrantel embonate has 
been known as an antiparasitic drug mostly against 
gastrointestinal nematodes [12]. In veterinary 
medicine for small animal practice, ivermectin and
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Table 4  Selectivity of the branded drug ‘Cardomec Chewable P’ and the generic drug ‘Ivermec PI’ when presented 
simultaneously to dogs 
 
 
pyrantel embonate have been used chiefly as a 
prophylactic agent against canine dirofilariasis [1, 2] 
and as an anti-parasitic agent against roundworms 
and hookworms [12], respectively, in dogs and 
domestic cats. The drugs evaluated in the present 
study were a branded drug ‘Cardomec Chewable P’ 
and its generic drug ‘Ivermec PI’, both of which use 
ivermectin and pyrantel embonate as active 
ingredients and which have been manufactured as 
beef-based chewable formulations for prophylaxis of 
canine dirofilariasis and also for elimination of 
gastrointestinal roundworms and hookworms [7]. 
   The chewable formulation is a characteristic 
dosage form in a category of veterinary drugs. It is 
designed to be consumed voluntarily by dogs and cats 
by containing highly preferred component(s) such as 
beef, chicken, and other animal/plant materials as a 
part of pharmaceutical excipients. Drugs formulated 
in a chewable form are expected to be very 
convenient, especially in the case of drugs such as 
prophylactics against dirofilariasis, which are often 
administered to animals by their guardians in their 
home. However, it is desirable that the palatability of 
the drugs will be confirmed before prescribing them 
for animals. 
   We earlier reported the high palatability of 
‘Cardomec Chewable P’ and ‘Ivermec PI’, with the 
results that the drugs were consumed voluntarily, 
respectively, by 97 of 100 dogs and by 198 of 200 
dogs [10, 14]. By contrast, these two trials were 
conducted separately using different dogs. The 
palatability of the two drugs had not been compared 
directly in any prior study. To compare the 
palatability of the two drugs, this study used the same 
dogs for evaluating the voluntary consumption of the 
drugs, and obtained the results that ‘Cardomec 
Chewable P’ and ‘Ivermec PI’ were voluntarily 
consumed, respectively, by 96% and 98.5% of the 
dogs. These results corresponded well with those 
obtained from our early studies [10, 14]. 
   When comparing the times until the dogs 
consume ‘Cardomec Chewable P’ and ‘Ivermec PI’, 
first quartile, second quartile (median), and third 
quartile were 4 s, 6 s, and 8 s for the former, and 2 s, 
4 s, and 6 s for the latter drug. These results were also 
almost identical to those used in earlier studies [10, 
14]. 
   Based on the facts in our early studies described 
above [10, 14] and results of the present study, it is 
considered that the palatability of the drugs is higher 
for ‘Ivermec PI’ than ‘Cardomec Chewable P’. The 
higher palatability of ‘Ivermec PI’ is expected to be 
bolstered from results obtained for selectivity in the 
present study. 
   Some dogs voluntarily consumed only one or 
neither drug. Many of these dogs were known to have 
an unbalanced diet, according to their guardians. 
Avoidance of drug consumption might have been 
unavoidable in a few dogs. 
   The two evaluated drugs, ‘Cardomec Chewable 
P’ and ‘Ivermec PI’, contain the same active 
ingredients with the same contents. They use beef as 
a pharmaceutical excipient. However, the respective 
origins and qualities of the beef should be considered 
as different between the two drugs. Other excipients 
are also thought to be different between the two [9]. 
Differences in the palatability of the two drugs in 
dogs are thought to be attributable to differences in 
the excipients, such as beef. Regarding voluntary 
consumption, the times until the intake might not be 
important. However, quicker consumption of the drug 
will engender the reduction of time and effort for 
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medication. 
   With respect to the safety of the evaluated drugs, 
although only general findings were observed 
macroscopically in this study, no adverse event was 
noticed. Considering past reports of the safety of the 
branded [5] and this generic [6] drugs, there was no 
apprehension about medication using the drugs. 
   Food allergies have attracted notice in recent 
years in dogs; some dogs are known to have beef 
allergies [11, 13, 20], although no dogs examined for 
this study developed allergy symptoms after 
medication. The branded drug with beef-based 
chewable formulations of ivermectin and pyrantel 
embonate has been used worldwide for many years [4, 
5, 15, 16, 18, 19], without remarkable trouble with 
food allergy. Accordingly, the possibility is slight that 
the drugs developed beef allergy symptoms in dogs. 
However, for dogs that had been diagnosed as having 
beef allergies, sufficient attention must be devoted in 
case something happens. 
   The evaluated chewable products will often be 
administered for prophylaxis of canine dirofilariasis, 
rather than for elimination of roundworms and 
hookworms. For heartworm prevention, the drug is 
administered to dogs once a month for at least 6–7 
months each year, from one month after appearance 
to one month after disappearance of mosquitoes, 
mostly at home by their guardians. The drugs which 
are consumed voluntarily by animals are expected to 
be quite convenient because they will be treated 
easily even by guardians who are not experienced 
with administering medication. 
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